Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

Review of Clinical Cancer Research Methodology of Botanical Agents

한약 및 천연물의 항암 임상연구 방법론에 대한 고찰

  • Oh, Hye Kyung (Department of Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Lee, Jee Young (Department of Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Ryu, Han Sung (Department of Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Yoon, Seong Woo (Department of Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong)
  • 오혜경 (강동경희대학교병원 한방암센터 한방내과) ;
  • 이지영 (강동경희대학교병원 한방암센터 한방내과) ;
  • 류한성 (강동경희대학교병원 한방암센터 한방내과) ;
  • 윤성우 (강동경희대학교병원 한방암센터 한방내과)
  • Received : 2015.03.28
  • Accepted : 2015.04.20
  • Published : 2015.04.25
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The cancer incidence and cancer burden is increasing. In addition, the use of botanical agents in cancer care is increasing. This article aims to review a research strategy for botanical agents. Methods : The clinical studies of anticancer botanical agents and the papers about clinical research methodology of botanical agents were reviewed. Results : In phase I study, safety confirmation, optimal dose determination and drug interaction study are important. Most botanical agents have low toxicity and some have non-monotone dose response. Therefore, dose-response curve must be evaluated separately from the dose-toxicity curve to determine optimal dose. Although anticancer botanical agents can't shrink tumor size rapidly, they do extend survival. So, in phase II study, response should be evaluated by the survival. Conclusions : Clinical research of botanical agents in cancer is different from traditional methods and strategies. Considering the characteristics of botanical agents and experimental mechanism is necessary in conducting botanical based clinical trials.

Keywords

References

  1. 보건복지부 중앙암등록본부, 2009년 국가암등록통계, 2011 (http://www.cancer.go.kr)
  2. 통계청, 2013년 사망원인통계 결과, 2014 (http://www.kostat.go.kr)
  3. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 83(4):777-82, 1998 https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
  4. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E, Use of complementary and alternative medicine in cancer patients: a Europnean survey, Ann Oncol. 16:655-663, 2005 https://doi.org/10.1093/annonc/mdi110
  5. Cragg GM, Newman DJ, Plants as a source of a anti-cancer agents, J Ethnopharmacol. 100:72-79, 2005 https://doi.org/10.1016/j.jep.2005.05.011
  6. Vickers AJ, Kuo J, Cassileth BR. Unconventional anticancer agents: a systematic review of clinical trials. J Clin Oncol. 24(1):136-40, 2006 https://doi.org/10.1200/JCO.2005.03.8406
  7. Vickers AJ, How to design a phase I trial of an anticancer botanical, J Soc integr Oncol. 4(1):46-51, 2006
  8. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RY, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R, Pilot Study of Huachansu in Patients With Hepatocellular Carcinoma, Non small-Cell Lung Cancer, or Pancreatic Cancer, Cancer. 115:5309-5318, 2009 https://doi.org/10.1002/cncr.24602
  9. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL, A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer, Breast Cancer Res Treat. 120:111-118, 2010 https://doi.org/10.1007/s10549-009-0678-5
  10. Deng G, Lin H, Seidman A, Fornier M, Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B, A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects, J Cancer Res Clin Oncol. 135:1215-1221, 2009 https://doi.org/10.1007/s00432-009-0562-z
  11. McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK, Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer. 12:454-62, 2004 https://doi.org/10.1007/s00520-004-0598-1
  12. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A, Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 94:1247-1249, 2002 https://doi.org/10.1093/jnci/94.16.1247
  13. Cassileth BR, Rizvi N, Deng G, Yeung KS, Vickers A, Guillen S, Woo D, Coleton M, Kris MG, Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients, Cancer Chemother Pharmacol. 65:67-71, 2009 https://doi.org/10.1007/s00280-009-1003-z
  14. Vickers AJ, Phase II designs for anticancer botanicals and supplements, J Soc Integr Oncol. 7(1):35-40, 2009
  15. Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, Liu SH, Cheng YC, First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer, Cancer Chemother Pharmacol. 73:373-380, 2014 https://doi.org/10.1007/s00280-013-2359-7
  16. Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L, Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas, Br J Cancer. 107:411-416, 2012 https://doi.org/10.1038/bjc.2012.283
  17. Attia A, Rapp SR, Case LD, D'Agostino R, Lesser G, Naughton M, McMullen K, Rosdhal R, Shaw EG, Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood, J Neurooncol. 109:357-363, 2012 https://doi.org/10.1007/s11060-012-0901-9
  18. Vickers AJ, Which botanicals or other unconventional anticancer agents should we take to clinical trial? J Soc Integr Oncol. 5(3):125-129, 2007 https://doi.org/10.2310/7200.2007.011
  19. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 51(10):557-564, 2002 https://doi.org/10.1007/s00262-002-0321-3
  20. Vickers AJ, How to design a phase I trial of an anticancer botanical, J Soc Integr Oncol. 4(1):46-51, 2006
  21. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 1;62(9):2474-2477, 2002